COMPARISON OF INTRAVENOUS LABETALOL AND HYDRALAZINE FOR THE CONTROL OF SEVERE HYPERTENSION IN PREGNANCY: A RANDOMIZED CONTROLLED TRIA

Not Applicable

• Conditions: Severe hypertension in pregnancy; Cardiology

• Registration Number: PACTR202010738538062
• Lead Sponsor: MUHAMMAD Sagir

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-09-30
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 120

Inclusion Criteria

• Consenting pregnant women with severe hypertension in pregnancy with systolic blood pressure (SBP) of at least 160 mmHg and/or diastolic blood pressure (DBP) of at least 110 mmHg.
• Gestational age of 28 weeks or more which will be determined based on ultrasound scan or last menstrual period.
• Live singleton fetus with normal fetal heart rate.

Exclusion Criteria

•All women with cardiac disease such as heart block, ischaemic heart disease, and hypertensive cardiac disease.
•Asthma
•History of allergy to either hydralazine or labetalol.
•Chronic medical disorder such as chronic kidney disease and diabetes mellitus.
•Women with haemoglobinopathy such as HbSS.
•Multiple gestation.
•Preterm labour at gestational age of less than 34 weeks
•Women who are already on other antihypertensive drugs.
•Patients with stroke
•Unconscious patients
•Patients with HELLP syndrome and liver disease
•Presence of fetal distress
•Non consenting women

Study & Design

• Study Type: Interventional
• Study Design: Not specified